Clinical trial · Interventional
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies
NCT00858572CI-TRIAL-00015650completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| CML | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
| Myeloproliferative Disorders | Myeloproliferative Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| STA-9090 (ganetespib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Cohort
- interventionNames
- Drug: STA-9090 (ganetespib)
Primary outcomes (3)
- measure
- To characterize the safety and tolerability of STA-9090 (ganetespib) in subjects with hematologic malignancies
- timeFrame
- Feb 2011
- measure
- To assess preliminary evidence of anti-neoplastic activity
- timeFrame
- Feb 2011
- measure
- To assess the pharmacokinetics of STA-9090 (ganetespib) when administered as a short-term intravenous infusion
- timeFrame
- Feb 2011
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria * Males and females 18 years or older * Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol * Must have acceptable organ function during screening as defined in the protocol Exclusion Criteria * Pregnant or breast-feeding women * Patients must meet the washout periods for prior chemotherapies and radiation * History of stroke within 6 months of treatment * Poor venous access for study drug administration * Treatment with chronic immunosuppressants * Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation
References
Publications (0)
Data not yet available
No reference posted for this study.